Figure 5

Single gavage with CBD at 246, 738, or 2460 mg/kg produced dose-dependent hepatotoxic effects in mice. Body weight changes, liver-to-body weight ratios, and intrahepatic total glutathione concentrations at 24 hours indicate significant liver burden at the highest doses.

Figure 6

Sub-acute CBD administration (10 daily doses at 61.5-615 mg/kg) produced cumulative hepatic effects. This figure presents body weight curves and liver enzyme data from the two-week dosing protocol.

Figure 7

Single CBD gavage induced significant changes in hepatic cytochrome P450 and UDP-glucuronosyltransferase expression. Quantitative real-time PCR data demonstrate dose-dependent upregulation of these xenobiotic-metabolizing enzymes at 24 hours post-treatment.

Figure 8

Hematoxylin and eosin-stained liver sections reveal dose-dependent histomorphological changes after 2-week CBD administration. Mice receiving 615 mg/kg CBD exhibited notable hepatocellular alterations compared to vehicle controls and lower-dose groups.

Figure 10

Hepatic gene expression profiling after sub-acute CBD treatment reveals broader metabolic impacts. This figure presents transcriptomic data on stress-response and metabolism-related genes in the liver.

Figure 11

Two-week CBD administration produced sustained changes in cytochrome P450 and UDP-glucuronosyltransferase gene expression. Quantitative PCR data collected 6 hours after the last gavage indicate persistent hepatic enzyme induction at higher CBD doses.